RXi Pharmaceuticals (NASDAQ:[[ticker:RXII]]), a Worcester, MA-based biotech focused on RNA interference treatments, has priced a public offering of common stock and warrants expected to gross $8.1 million, according to a press release. The company, whose big-named scientific advisor is RNAi luminary and Nobel laureate Craig Mello, says that the public offering is expected to close around March 4. The firm plans to use the net proceeds of the offering, estimated at $7.3 million, for general corporate purposes.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
